These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Virus-specific T cell immune response in children and adolescents with chronic hepatitis B virus infection.
    Author: Fischler B, Nyström J, Björnsdottir T, Lindh G, Hultgren C.
    Journal: J Pediatr Gastroenterol Nutr; 2007 Jul; 45(1):75-83. PubMed ID: 17592368.
    Abstract:
    OBJECTIVES: To study the hepatitis B-specific T cell-mediated immune response in chronically infected children and adolescents. PATIENTS AND METHODS: In all, 36 HBsAg-positive patients, 2 to 19 years old, were included. There were 9 HBeAg-positive patients with normal levels of alanine aminotransferase (ALT) (group 1), 18 HBeAg-positive patients with elevated ALT (group 2), and 9 HBeAg-negative, anti-HBe-positive patients (group 3). Four patients in group 2 were treated with interferon during the study. In all patients, HBcAg-specific T cell proliferation and ALT levels were prospectively studied in repeated samples for a mean follow-up time of 1.6 years. The baseline HBV-DNA and plasma cytokine levels were determined, and genotypes were analyzed. RESULTS: The percent of patients with at least 1 sample indicating T cell proliferation was 55% in group 1 and 89% in groups 2 and 3, respectively (P = 0.07 group 1 vs group 2, P = 0.013 group 1 vs the combined groups 2 and 3). Tendencies for positive correlations between the degree of T cell proliferation and ALT levels were noted in groups 1 and 3 and for negative correlations in HBeAg seroconverting patients of group 2. In patients with successful interferon treatment, a pattern of more vigorous T cell proliferation than in patients with spontaneous seroconversion was noted. CONCLUSIONS: A majority of patients showed signs of ongoing T cell proliferation. The continuation of the T cell-mediated immune response seems to be of importance in maintaining the HBeAg seroconversion over time.
    [Abstract] [Full Text] [Related] [New Search]